Generali Asset Management’s Vistra VST Stock Holding History

Generali Asset Management’s Portfolio VST Stock Details VST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$757K	Sell	4,770 -6,065	-56%	-$941K	0.01%	363
2026 Q1	$1.63M	Buy	+10,835	New	+$1.75M	0.03%	331

Other funds holding VST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Generali Asset Management's VST Position: Q2 2026 in Review

Generali Asset Management reduced its Vistra (VST) stake by 56% in Q2 2026, selling an estimated $941K and leaving 4,770 shares worth $757K. The position accounts for 0.01% of the portfolio, ranked #363.

Generali Asset Management first reported a position in VST in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.63M in Q1 2026. 1,406 funds tracked by Wall St. Rank hold VST as of Q2 2026.

Generali Asset Management held 4,770 shares of Vistra worth $757K as of Q2 2026.
Generali Asset Management sold 6,065 Vistra shares in Q2 2026, an estimated $941K.
Vistra made up 0.01% of Generali Asset Management's portfolio in Q2 2026, its #363 holding.
Generali Asset Management first reported a position in Vistra in Q1 2026 and has held it in 2 quarters since.
Generali Asset Management's Vistra position peaked at $1.63M in Q1 2026.
1,406 funds tracked by Wall St. Rank held Vistra as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.